Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  NeuBase Therapeutics, Inc.    NBSE

NEUBASE THERAPEUTICS, INC.

(NBSE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo NeuBase Therapeutics, Inc.
NeuBase Therapeutics, Inc. is a pre-clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.

Number of employees : 9 people.
Managers
NameAgeSinceTitle
Dietrich A. Stephan, Dr.492019President, Chief Executive Officer & Director
William R. Mann, Dr.592020Chief Operating Officer
Samuel I. Backenroth352019Chief Financial Officer, Secretary & Treasurer
Robert Friedlander--Consulting Chief Medical Officer
Danith Ly, Dr.-2019Chief Scientific Officer
Dov A. Goldstein, Dr.512019Independent Director
Diego Miralles, Dr.562019Independent Director
Franklyn G. Prendergast, Dr.742019Independent Director
Eric I. Richman582019Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 23,122,353 18,043,248 78.0% 0 0.0% 78.0%
Shareholders
NameEquities%
Dietrich A. Stephan 2,560,164 11.1%
Greenlight Capital, Inc. 1,903,227 8.23%
Shivaji Thadke 1,019,055 4.41%
Carnegie Mellon University 939,412 4.06%
Renaissance Technologies LLC 896,078 3.88%
Shawn M. Titcomb 861,394 3.73%
Kershner Trading Americas LLC 467,600 2.02%
Millennium Management LLC 419,325 1.81%
OrbiMed Advisors LLC 371,114 1.61%
BlackRock Fund Advisors 260,903 1.13%
Company contact information
NeuBase Therapeutics, Inc.
700 Technology Drive
Third floor
Pittsburgh, PA 15219

Phone : +1.646.45.1790
Web : http://www.neubasetherapeutics.com
Sector Biotechnology & Medical Research - NEC